An expert discusses how vitiligo significantly affects patients’ psychosocial health due to its visible nature, unpredictable course, slow treatment response, and particularly severe impact on younger ...

Medically reviewed by William Truswell, MD Vitiligo is an autoimmune skin disorder affecting about 1 in 100 people. It is characterized by a loss of pigment (coloring) in skin patches that appear ...

Vitiligo is a condition that affects millions worldwide, yet it remains widely misunderstood. Characterised by white patches ...

New microbial therapy slows the progression of vitiligo in mice An NU study found a natural compound derived from gut-friendly bacteria that significantly slows down the progression of vitiligo ...

The presence of clinical markers in patients with vitiligo may have an association with worsening prognoses and rapid disease progression, according to a perspective cohort study published in JAMA ...

Leading companies, such as Incyte Corporation, TWi Biotechnology, Amgen, Pfizer, Arcutis Biotherapeutics, AnaptysBio, and others, are actively advancing promising drug candidates aimed at improving ...

Meeting Coverage > AAD Age at Vitiligo Onset Not a Major Factor — Early onset associated with progression but not treatment response. by Charles Bankhead, Senior Editor, MedPage Today August 22 ...

Vitiligo can be mild by appearing as only a few depigmented patches on the face or hands or significant involvement on the ... There is not any medication that can stop the progression of vitiligo.

The progression of vitiligo is difficult to predict. Sometimes, the patches stop forming without treatment. However, pigment loss can spread. Eventually, it may involve most of the skin's surface.

(HealthDay News) — Confetti-like depigmentation may be a marker of rapidly progressing vitiligo, according to a review published in the August issue of the Journal of the American Academy of ...

Vitiligo is a difficult condition to treat, ... Finally, sunlight exposure with vitamin B12 and folic acid has been reported to arrest disease progression in 64% of patients in one study, ...